-
Dec 11, 2024 | 
insights.citeline.com | John H Davis
Lundbeck's Vyepti Sales Pick Up Against Pandemic HeadwindsNarrows Financial Guidance For 202004 Nov 2020 • By John DavisLundbeck also makes progress in the third quarter with its early clinical-stage neuroscience candidates and indication extension studies for its psychiatry products, while confirming and narrowing revenues and earnings forecasts for the year.
-
Nov 20, 2024 | 
selmasun.com | John H Davis
Subscribe to our print or digital edition.
-
Nov 6, 2024 | 
insights.citeline.com | Lisa LaMotta |John H Davis |Sten Stovall
Deal Watch: Auxilium Accepts Endo Buyout Rather Than Completing Purchase Of QLT Shell13 Oct 2014 • By Lisa LaMotta, John Davis, and Sten StovallActavis continues filling out its portfolio by acquiring Durata, but leaves room for other transformational deals. Impax moves strongly into generics and adds an FDA-licensed manufacturing site in buying three companies under the Tower Holdings umbrella.
-
Nov 1, 2024 | 
fresnobee.com | John H Davis
-
Oct 22, 2024 | 
insights.citeline.com | John H Davis
Induced pluripotent stem cells promising in haemophilia25 Feb 2005 • By John DavisInduced pluripotent (iPS) stem cells, injected into the livers of haemophiliac mice, prevented the animals from bleeding to death, report Dr Dan Xu and colleagues in the Proceedings of the National Academy of Sciences (January 20th, p 665).
-
Oct 16, 2024 | 
insights.citeline.com | John H Davis
Lyrica rejected for fibromyalgia by the CHMP28 Apr 2009 • By John DavisPfizer's anticonvulsant, pregabalin (Lyrica), has received a negative opinion from the EU's CHMP for use in fibromyalgia, an additional indication. Benefits with pregabalin had not been shown in either the short or long term, the committee concluded.
-
Oct 15, 2024 | 
insights.citeline.com | John H Davis
UCB Aims To Tailor Myasthenia Gravis Therapy Options To PatientsWith Two Late-Stage Candidates04 Mar 2021 • By John DavisBelgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year. Brussels, Where UCB is headquartered • Source: Shutterstock
-
Oct 15, 2024 | 
insights.citeline.com | John H Davis
Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia StudyUS BLA Submission By End Of 202027 May 2020 • By John DavisThe European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries. A neuromuscular junction; dysfunctional junctions are associated with myasthenia gravis • Source: Shutterstock
-
Oct 15, 2024 | 
insights.citeline.com | Melanie Senior |Wendy Diller |John H Davis |Paul Bonanos
Deals Of The Week: Shire/Janssen, Pfizer/SFJ Pharma, AstraZeneca/IMS Health16 Jan 2012 • By Melanie Senior, Wendy Diller, John Davis, and Paul BonanosBesides the latest acquisition in the hepatitis C space, the week of the JP Morgan Healthcare Conference saw a spate of deals, including Shire doubling down on its bet on GI drug Resolor and Pfizer inking a pair of deals.
